{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:48:04Z","timestamp":1788994084197,"version":"build-2803163510"},"reference-count":57,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate potential drug\u2013drug interactions of ubrogepant and atogepant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ubrogepant and atogepant, calcitonin gene\u2010related peptide (CGRP) receptor antagonists, are recently approved drugs for acute and preventive treatment of migraine, respectively. For patients with migraine who are prescribed atogepant for the preventive treatment of migraine, health care providers could prescribe ubrogepant for the acute treatment of breakthrough migraine attacks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A phase Ib, multi\u2010center, open\u2010label, fixed\u2010sequence study was conducted in participants diagnosed with migraine for at least 1\u2009year. To assess the primary objective of pharmacokinetic interactions in this phase I trial, the highest United States Food and Drug Administration\u2010approved individual dose strengths of atogepant (60\u2009mg once daily) and ubrogepant (100\u2009mg) were utilized, with ubrogepant being administered on a fixed\u2010dose schedule every 3\u2009days, regardless of whether a participant was experiencing a migraine attack. Secondary endpoints included safety and tolerability. Clinical safety measurements were monitored throughout the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 31 participants enrolled, 26 completed the study. A single dose of ubrogepant had no statistically significant effect on atogepant pharmacokinetics. Co\u2010administration of ubrogepant with atogepant resulted in a 19% increase (geometric mean ratio 118.80, 90% confidence interval [CI] 108.69\u2013129.84) in the ubrogepant area under the plasma concentration\u2010time curve and a 26% increase (geometric mean ratio 125.63, 90% CI 105.58\u2013149.48) in the ubrogepant maximum plasma concentration. These statistically significant changes in ubrogepant exposure were not clinically meaningful, and no new safety concerns were identified for the combination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The combination use of atogepant and ubrogepant was safe and well tolerated in adult participants with a history of migraine enrolled in the study. Pharmacokinetic changes during co\u2010administration were not clinically meaningful.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14433","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T07:34:08Z","timestamp":1672904048000},"page":"322-332","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Phase Ib, open\u2010label, fixed\u2010sequence, drug\u2013drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine"],"prefix":"10.1111","volume":"63","author":[{"given":"Andrew M.","family":"Blumenfeld","sequence":"first","affiliation":[{"name":"Headache Center of Southern California  Carlsbad California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Boinpally","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology AbbVie Inc.  Madison New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"De\u00a0Abreu\u00a0Ferreira","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology AbbVie Inc.  Madison New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Trugman","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology AbbVie Inc.  Madison New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Dabruzzo","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology AbbVie Inc.  Madison New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ailani","sequence":"additional","affiliation":[{"name":"MedStar Georgetown University Hospital  Washington District of Columbia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Lipton","sequence":"additional","affiliation":[{"name":"The Saul R. Korey Department of Neurology Albert Einstein College of Medicine  Bronx New York USA"},{"name":"Department of Psychiatry and Behavioral Sciences Albert Einstein College of Medicine  Bronx New York USA"},{"name":"Department of Epidemiology &amp; Population Health Albert Einstein College of Medicine  Bronx New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,1,5]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32279-7"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252808.97649.21"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15440-8"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14103"},{"key":"e_1_2_13_6_1","doi-asserted-by":"crossref","unstructured":"BuseDC ReedML FanningKM DabruzzoBL LiptonRB.Characterizing preventive treatment gaps in migraine: interim results from the CaMEO\u2010international study United States sample. Poster (IOR\u201005) presented at: American Headache Society 64th Annual Scientific Meeting; June 9\u201312 2022; Denver CO. Accessed September 12 2022. doi:10.1111\/head.14317","DOI":"10.1111\/head.14317"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000335946.53860.1d"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001256"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70005-3"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-013-2433-1"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-020-01839-5"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13456"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/298240a0"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13791"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102421989601"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420938652"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14062"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13601"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211000311"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30234-9"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035908"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007856"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000932"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12917"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01644-5"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01264-5"},{"key":"e_1_2_13_28_1","doi-asserted-by":"crossref","unstructured":"Pozo\u2010RosichP AilaniJ AshinaM et al.Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial. Poster (LB\u2010P\u2010104) presented at: American Headache Society 64th Annual Scientific Meeting; June 9\u201312 2022; Denver CO. Accessed September 12 2022. doi:10.1111\/head.14317","DOI":"10.1111\/head.14317"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-021-01034-5"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13862"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14095"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.2217\/pmt-2021-0073"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1610"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1034"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/2515816320905082"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14089"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1211"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1696"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13510"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102411398399"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000771"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813049"},{"key":"e_1_2_13_44_1","unstructured":"Guidance for Industry E9 Statistical Principles for Clinical Trials.U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) September 1998 ICH. Accessed September 12 2022.https:\/\/www.fda.gov\/media\/71336\/download"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-0979-y"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-017-0463-4"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14051"},{"key":"e_1_2_13_48_1","unstructured":"Allergan USA Inc. QULIPTA (atogepant) [package insert].U.S. Food and Drug Administration website. Revised September 2021. Accessed March 21 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215206Orig1s000lbl.pdf"},{"key":"e_1_2_13_49_1","unstructured":"Allergan USA Inc.UBRELVY (ubrogepant) [package insert]. U.S. Food and Drug Administration website. Revised December 2019. Accessed August 16 2021.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211765s000lbl.pdf"},{"key":"e_1_2_13_50_1","doi-asserted-by":"crossref","unstructured":"BoinpallyR TrugmanJM.Effect of high fat meal on the pharmacokinetics of an immediate release atogepant tablet. Poster presented at: American Headache Society 64th Annual Scientific Meeting; June 9\u201312 2022; Denver CO. doi:10.1111\/head.14317","DOI":"10.1111\/head.14317"},{"key":"e_1_2_13_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14099"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19074018"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13682"},{"key":"e_1_2_13_54_1","unstructured":"AbbVie Inc.Study to assess adverse events when ubrogepant tablets in combination with atogepant tablets are used to treat adult participants with migraine. ClincialTrials.gov identifier: NCT05264129. Updated April 11 2022. Accessed April 11 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05264129"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfac051"},{"key":"e_1_2_13_56_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12121180"},{"key":"e_1_2_13_57_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024221083544"},{"key":"e_1_2_13_58_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420983282"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14433","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.14433","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14433","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T08:59:08Z","timestamp":1762073948000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,5]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1111\/head.14433"],"URL":"https:\/\/doi.org\/10.1111\/head.14433","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,5]]},"assertion":[{"value":"2022-07-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}